Compare EVGO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | RZLT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.1M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | EVGO | RZLT |
|---|---|---|
| Price | $2.79 | $3.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $5.82 | ★ $9.17 |
| AVG Volume (30 Days) | ★ 3.5M | 2.8M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.28 | N/A |
| Revenue Next Year | $29.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $1.07 |
| 52 Week High | $5.18 | $11.46 |
| Indicator | EVGO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 49.49 |
| Support Level | $2.67 | $3.42 |
| Resistance Level | $3.32 | $4.09 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 16.15 | 43.41 |
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.